These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 26615912)

  • 41. Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis.
    Abd El-Kader SM; Al-Shreef FM; Al-Jiffri OH
    Afr Health Sci; 2016 Mar; 16(1):242-9. PubMed ID: 27358638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A vegetarian diet does not protect against nonalcoholic fatty liver disease (NAFLD): A cross-sectional study between Buddhist priests and the general population.
    Choi SH; Oh DJ; Kwon KH; Lee JK; Koh MS; Lee JH; Kang HW
    Turk J Gastroenterol; 2015 Jul; 26(4):336-43. PubMed ID: 26039004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
    Della Corte C; Carpino G; De Vito R; De Stefanis C; Alisi A; Cianfarani S; Overi D; Mosca A; Stronati L; Cucchiara S; Raponi M; Gaudio E; Byrne CD; Nobili V
    PLoS One; 2016; 11(12):e0168216. PubMed ID: 27977757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial.
    Lorvand Amiri H; Agah S; Mousavi SN; Hosseini AF; Shidfar F
    Arch Iran Med; 2016 Sep; 19(9):631-8. PubMed ID: 27631178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Olive oil lessened fatty liver severity independent of cardiometabolic correction in patients with non-alcoholic fatty liver disease: A randomized clinical trial.
    Rezaei S; Akhlaghi M; Sasani MR; Barati Boldaji R
    Nutrition; 2019 Jan; 57():154-161. PubMed ID: 30170304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study of Clinical Profile of Patients of Non Alcoholic Fatty Liver Disease and its Association with Metabolic Syndrome.
    Gaharwar R; Trikha S; Margekar SL; Jatav OP; Ganga PD
    J Assoc Physicians India; 2015 Jan; 63(1):12-6. PubMed ID: 26591121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease.
    Chung GE; Kim D; Kwak MS; Yang JI; Yim JY; Lim SH; Itani M
    Clin Mol Hepatol; 2016 Mar; 22(1):146-51. PubMed ID: 27044765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of vitamin D supplementation on metabolic profiles and liver function in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Tabrizi R; Moosazadeh M; Lankarani KB; Akbari M; Heydari ST; Kolahdooz F; Samimi M; Asemi Z
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S975-S982. PubMed ID: 28751149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease.
    Sangouni AA; Ghavamzadeh S; Jamalzehi A
    Diabetes Metab Syndr; 2019; 13(3):2260-2265. PubMed ID: 31235166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis.
    Katsagoni CN; Georgoulis M; Papatheodoridis GV; Panagiotakos DB; Kontogianni MD
    Metabolism; 2017 Mar; 68():119-132. PubMed ID: 28183444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial.
    Sangouni AA; Mohammad Hosseini Azar MR; Alizadeh M
    Br J Nutr; 2020 Aug; 124(4):450-456. PubMed ID: 32312333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease.
    Cerletti C; Colucci M; Storto M; Semeraro F; Ammollo CT; Incampo F; Costanzo S; De Bartolomeo G; Portincasa P; Barone M; Di Castelnuovo A; Semeraro N; Iacoviello L; de Gaetano G
    Br J Nutr; 2020 Jan; 123(2):190-197. PubMed ID: 31554528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO).
    Barrea L; Muscogiuri G; Annunziata G; Laudisio D; de Alteriis G; Tenore GC; Colao A; Savastano S
    Nutrients; 2019 Jun; 11(6):. PubMed ID: 31185686
    [No Abstract]   [Full Text] [Related]  

  • 56. Vitamin D nutritional status and its relationship with metabolic changes in adolescents and adults with severe obesity.
    Teixeira JS; Bull Ferreira Campos A; Cordeiro A; Pereira SE; Saboya CJ; Ramalho A
    Nutr Hosp; 2018 Aug; 35(4):847-853. PubMed ID: 30070873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meta-analysis: vitamin D and non-alcoholic fatty liver disease.
    Eliades M; Spyrou E; Agrawal N; Lazo M; Brancati FL; Potter JJ; Koteish AA; Clark JM; Guallar E; Hernaez R
    Aliment Pharmacol Ther; 2013 Aug; 38(3):246-54. PubMed ID: 23786213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.
    Younossi ZM; Otgonsuren M; Venkatesan C; Mishra A
    Metabolism; 2013 Mar; 62(3):352-60. PubMed ID: 22999011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of Cardiovascular Parameters in Obese Children and Adolescents with Non-Alcoholic Fatty Liver Disease.
    Eklioğlu BS; Atabek ME; Akyürek N; Alp H
    J Clin Res Pediatr Endocrinol; 2015 Sep; 7(3):222-7. PubMed ID: 26831557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.